Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SNY
SNY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNY News
Sanofi Reports Positive Results from Three Phase 3 Trials of Amlitelimab
1d ago
NASDAQ.COM
Zacks Research Daily: Major Stock Analyses
2d ago
NASDAQ.COM
EMA Endorses Sanofi's Scarlisa for On-Body Injection Approval
2d ago
seekingalpha
Biotech Landscape Update: Regulatory Approvals and Mergers
2d ago
NASDAQ.COM
EMA Recommends Approval of Sarclisa Subcutaneous Injection for Multiple Myeloma
2d ago
NASDAQ.COM
Anti-Vaccine Group Seeks Expansion of Vaccine Injury List
3d ago
seekingalpha
Senate Reaches Bipartisan Deal to Cap Insulin Costs at $35
4d ago
seekingalpha
U.S. Senators Reach Agreement to Cap Insulin Prices
4d ago
stocktwits
Bipartisan Agreement Among US Senators Aims to Limit Insulin Prices to $35 – SNY, LLY, NVO Stocks Rise in Pre-Market Trading
4d ago
stocktwits
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
5d ago
NASDAQ.COM
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
6d ago
NASDAQ.COM
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
6d ago
Globenewswire
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
6d ago
Yahoo Finance
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
6d ago
Yahoo Finance
Sanofi and Regeneron's Dupixent Receives Approval in Japan as the First Targeted Treatment for Adults with Bullous Pemphigoid
6d ago
moomoo
AstraZeneca and Sanofi Expand R&D Operations in China
Mar 20 2026
seekingalpha
Show More News
